Generation Bio Co. is a genetic medicine company, which focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. Its non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA, a novel cell-targeted lipid nanoparticle delivery system, or ctLNP, and an established, scalable capsid-free manufacturing process. The company was founded by Mark D. Angelino, Jason P. Rhodes, and Robert M. Kotin in 2016 and is headquartered in Cambridge, MA.
Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No trial data available
No approval data available
- DelveInsight's 2025 pipeline analysis reveals over five companies are actively developing Wilson Disease treatments, with ALXN1840 completing Phase III enrollment as a potential first-in-class targeted copper reduction therapy. - ALXN1840 has received Orphan Drug Designation in both the United States and European Union, positioning it as a promising once-daily oral treatment specifically designed to bind and eliminate excess copper from tissues and bloodstream. - The Wilson Disease pipeline includes diverse therapeutic approaches spanning gene therapies, small molecules, and targeted treatments across various development stages from preclinical to late-stage Phase III trials. - Market growth is driven by increasing prevalence and demand for better treatments, though high drug costs and lack of reimbursement policies present significant barriers to market expansion.
- Xoma Royalty has agreed to acquire Generation Bio, a struggling gene therapy developer, for approximately $4.29 per share in its latest "zombie biotech" acquisition. - Generation Bio raised $200 million in its 2020 IPO to develop lipid nanoparticle-based gene therapy technology but faced setbacks including disappointing preclinical results and workforce reductions. - The acquisition includes contingent value rights for shareholders, potentially providing additional payments from cash holdings, lease savings, Moderna partnership milestones, and proceeds from delivery technology sales. - Generation Bio recently slashed 90% of its workforce and began strategic review after touting RNA delivery technology for T cells, fitting Xoma's pattern of acquiring distressed biotech companies.
- Major pharmaceutical and biotech companies including Pfizer, Johnson & Johnson, Fate Therapeutics, and Generation Bio are implementing workforce reductions as part of industry-wide financial restructuring efforts. - Companies are shifting from broad R&D portfolios to focused pipeline optimization, with firms like Shattuck Labs and Relay Therapeutics narrowing their therapeutic focus to core projects with highest potential returns. - The layoffs reflect strategic responses to investor pressure for capital discipline, post-pandemic demand shifts, and the need to extend cash reserves while maintaining progress on lead clinical programs. - Industry consolidation and increased outsourcing to contract research organizations are driving operational realignment, as companies seek to reduce overhead costs and access specialized expertise without maintaining high-cost facilities.
- Biopharma companies continue to announce layoffs in 2025, driven by strategic realignments, pipeline reprioritizations, and challenging financial conditions. - Several companies, including Intellia Therapeutics and IGM Biosciences, are cutting a significant portion of their workforce to focus on key programs and extend cash runways. - These workforce reductions are often accompanied by discontinuation of certain drug development programs and a shift in strategic focus towards core assets. - The layoffs reflect a broader trend in the industry as companies adapt to evolving market dynamics and prioritize efficiency and long-term sustainability.
